

### **Amendments to the claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Original) A recombinant *Dermatophagoides pteronyssinus* Der p 1 protein allergen derivative wherein said allergen derivative has a significantly reduced allergenic activity compared to that the wild-type allergen in which said derivative has been genetically mutated and in which the mutant comprises the three following mutations: a mutation of the cysteine 71 residue, a mutation of the cysteine 103 residue and a mutation of the cysteine 117 residue.
2. (Original) A recombinant *Dermatophagoides pteronyssinus* Der p 1 protein allergen derivative wherein said allergen derivative has a significantly reduced allergenic activity compared to that the wild-type allergen in which said derivative has been genetically mutated and in which the mutant comprises a deletion of amino acid residues 147 to 160 of Der p 1 or residues 227-140 of ProDer p 1.
3. (Original) A recombinant mutant allergen having any of the sequences selected from the group consisting of: SEQ ID NO: 15, SEQ ID NO: 17.
4. (Currently Amended) An isolated nucleic acid molecule encoding a mutated version of an allergen as claimed in ~~any previous claim~~ claim 1.
5. (Original) A nucleic acid sequence according to claim 4 wherein the codon usage pattern resembles that of highly expressed mammalian genes.
6. (Currently Amended) An expression vector containing a nucleic acid of claim 4 ~~or 5~~.
7. (Currently Amended) A host cell transformed with a nucleic acid sequence of claim 4 ~~or 5~~ or with a vector as claimed in claim 6.
8. (Currently Amended) An immunogenic composition comprising a recombinant protein or mutant allergen as claimed in ~~any one of claims 1 to 3~~ claim 1, or an encoding polynucleotide as claimed in claim 4 ~~to 7~~, and, optionally, an adjuvant.
9. (Original) An immunogenic composition as claimed in claim 8, wherein the adjuvant is a preferential stimulator of Th1-type immune responses.
10. (Currently Amended) An immunogenic composition as claimed in claim 8 ~~or 9~~ wherein the adjuvant comprises one or more of 3D-MPL, QS21, a CpG

oligonucleotide, a polyethylene ether or ester or a combination of two or more of these adjuvants.

11. (Currently Amended) An immunogenic composition as claimed in ~~any of claims 8 to 10~~ claim 8 wherein the allergen is presented in an oil in water or a water in oil emulsion vehicle.
12. (Original) A immunogenic composition as claimed herein for use in medicine.
13. (Currently Amended) Use of a recombinant protein or mutant allergen as claimed in ~~any one of claims 1 to 3~~ claim 1 in the manufacture of a medicament for the treatment of allergy.
14. (Currently Amended) A method of treating a patient suffering from or preventing a patient susceptible to allergic responses, comprising administering to said individual an immunogenic composition as claimed in ~~claims 8 to 12~~ claim 8.
15. (Original) A *Dermatophagoides pteronyssinus* ProDer p 3 or PreProDer p 3 protein allergen or derivative thereof, wherein said ProDer p 3, PreProDer p 3 or allergen derivative has a significantly reduced allergenic activity compared to Der p 3.
16. (Original) An allergen or derivative as claimed in claim 15, wherein said allergen or derivative has been thermally treated.
17. (Original) A allergen or derivative as claimed in claim 15, wherein said allergen or derivative has been genetically mutated.
18. (Original) A allergen or derivative as claimed in claim 17, wherein the mutation comprises a mutation of a cysteine residue.
19. (Original) A recombinant allergen having the sequence of: SEQ ID NO:19.
20. (Currently Amended) An isolated nucleic acid molecule encoding a mutated version of an allergen as claimed in ~~any previous claim~~ claim 1.
21. (Original) An isolated nucleic acid molecule having the sequence of any of SEQ ID NOs.20 or 21.
22. (Currently Amended) An expression vector containing a nucleic acid of claim 20 ~~or 21~~.
23. (Currently Amended) A host cell transformed with a nucleic acid sequence of claim 20 ~~or 21~~ or with a vector as claimed in claim 22.
24. (Currently Amended) An immunogenic composition comprising a recombinant protein or mutant allergen as claimed in ~~any one of claims 15 to 19~~ claim 15, or an

encoding polynucleotide as claimed in claim 20 ~~to 21~~, and, optionally, an adjuvant.

25. (Original) An immunogenic composition as claimed in claim 24, wherein the adjuvant is a preferential stimulator of Th1-type immune responses.
26. (Currently Amended) An immunogenic composition as claimed in claim 24 ~~or 25~~ wherein the adjuvant comprises one or more of 3D-MPL, QS21, a CpG oligonucleotide, a polyethylene ether or ester or a combination of two or more of these adjuvants.
27. (Currently Amended) An immunogenic composition as claimed in ~~any one of claims 24 to 26~~ claim 24 wherein the allergen is presented in an oil in water or a water in oil emulsion vehicle.
28. (Original) A immunogenic composition as claimed herein for use in medicine.
29. (Currently Amended) Use of a recombinant protein or mutant allergen as claimed in ~~any one of claims 15 to 19~~ claim 15 in the manufacture of a medicament for the treatment of allergy.
30. (Currently Amended) A method of treating a patient suffering from or preventing a patient susceptible to allergic responses, comprising administering to said individual an immunogenic composition as claimed in ~~claims 24 to 28~~ claim 24.